ClinicalTrials.gg
CompletedNCT03386292Updated Dec 29, 2017

Urinary and Anal Incontinence in Tunisian Women

An observational study in Woman, sponsored by University of Monastir. Completed at 1 site in Tunisia. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-29.

Sponsored by University of Monastir · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
400
Ages
18 Years and older
Sex
Female
01

Study summary

The publications on prevalence and risk factors of urinary and anal incontinence in women were performed mainly in Europe and America. Consequently, result extrapolation to Tunisian population may not be a good practice which justifies this study and demonstrates its importance.

Read the detailed description

A cross-sectional study will be conducted among female doctors and nurses randomly selected from 3 large hospitals in the center of Tunisia. The prevalence of urinary incontinence and anal incontinence will be measured using validated questionnaires.

02

Conditions studied

  • Woman

Browse trials for

Keywords

  • prevalence
  • urinary incontinence
  • anal incontinence
  • risk factors
  • women
03

In context

Urinary Incontinence

986 studies on the registry are indexed under Urinary Incontinence; 183 are open to participants now.

This study's enrollment of 400 is above the median of 120 across 216 observational studies indexed under Urinary Incontinence.

Browse Urinary Incontinence studies →

Lead sponsor

University of Monastir is the lead sponsor of 114 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Female doctors and nurses working at Sahloul Hospital, Taher Sfar Hospital and Fattouma Bourguiba Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Professional seniority in the current service over than 6 months
  • Subject has given his consent

Exclusion criteria

Exclusion Criteria:

  • Resident
  • Intern
  • An ongoing pregnancy
  • A recent birth (less than 6 months)
  • A psychiatric disease
  • An acute or chronic kidney disease
  • Neurological disease
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
400 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prevalence of urinary incontinence

    The participant will be asked to fill out the urinary symptom profile questionnaire (USP). This questionnaire contains 13 items to assess stress urinary incontinence, urge urinary incontinence and dysuria. Each question is scored from 0 to 3 providing a maximal score of 9, 21 and 9 for stress urinary incontinence, urge urinary incontinence and dysuria respectively. Women diagnosed with both stress and urge urinary incontinence by the USP were classified as having mixed urinary incontinence.

    Time frame: 1 month

  2. Prevalence of anal incontinence

    The participant will be asked to fill out the anal incontinence Jorge and Wexner which contains five questions scored on a scale from zero (normal continence) to 20 (total incontinence).

    Time frame: 1 month

Secondary outcomes

  1. Risk factors for urinary and anal incontinence

    Time frame: 1 month

07

Study locations

1 site
  • Faculty of Medecine
    Monastir, 5019, Tunisia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Sep 2017, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2017
First posted
Dec 29, 2017
StartActual
Jun 16, 2017
Primary completionActual
Sep 30, 2017
CompletionActual
Sep 30, 2017
Last update
Dec 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03386292
Responsible party
Syrine GALLAS (Principal investigator, University of Monastir) — Principal investigator
First posted
Dec 29, 2017
Start date
Jun 16, 2017
Primary completion
Sep 30, 2017
Completion
Sep 30, 2017
Last update
Dec 29, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion